SCHEMBL2474635

SCHEMBL2474635

CN(C)CCC(NC(=O)Nc1ccc2c(c1)CCC2)c1ccc(C(=O)Nc2ccccc2N)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 10/20 0.50
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.45
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
MAPK14 Q16539 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
HDAC1 Q13547 4/20 0.43
HDAC3 O15379 2/20 0.43
HDAC2 Q92769 2/20 0.43
NCOR2 Q9Y618 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2474633 0.95 UTS2R (0.45) UTS2RNPC1RAB9ANFKB1NFKB2
SCHEMBL3834611 0.92 KMT2A (0.48) UTS2RNPC1RAB9ANFKB1NFKB2
SCHEMBL2476312 0.90 NPC1 (0.49) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3836235 0.90 NPC1 (0.48) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL3835163 0.89 HDAC1 (0.46) UTS2RNPC1RAB9ANFKB1NFKB2
SCHEMBL4388403 0.89 NPC1 (0.47) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL1482524 0.88 UTS2R (0.45) UTS2RNPC1RAB9ANFKB1NFKB2
SCHEMBL2472852 0.88 NPC1 (0.47) NPC1RAB9ANFKB1NFKB2RELA
SCHEMBL2474154 0.88 UTS2R (0.52) UTS2RNPC1RAB9AALDH1A1HDAC1
SCHEMBL2478981 0.87 NPC1 (0.42) NPC1RAB9ANFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 UTS2R 11/4885NPC1 989/4885RAB9A 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.